Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.
暂无分享,去创建一个
Max Wolf | Ivana Teodorovic | Randy D Gascoyne | Richard Klasa | Anton Hagenbeek | R. Gascoyne | E. Kimby | A. Hagenbeek | M. van Glabbeke | H. Holte | R. Marcus | M. V. van Oers | I. Teodorović | Martine van Glabbeke | A. Jack | R. Klasa | Andrew Jack | Marinus H J van Oers | Harald Holte | M. V. van't Veer | M. Wolf | Eva Kimby | Robert E Marcus | Mars Van't Veer | Andrej Vranovsky | Cynthia Rozewicz | Cynthia Rozewicz | A. Vranovský | M. V. Van Glabbeke
[1] S. Fagerholm,et al. alpha-Chain phosphorylation of the human leukocyte CD11b/CD18 (Mac-1) integrin is pivotal for integrin activation to bind ICAMs and leukocyte extravasation. , 2006, Blood.
[2] J. Lau,et al. Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in mice with targeted deficiency in the sialyltransferase ST6Gal I. , 2006, Blood.
[3] C. Dunbar,et al. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy. , 2006, Blood.
[4] K. Mills,et al. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. , 2006, Blood.
[5] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[6] R. Fisher,et al. New treatment options have changed the survival of patients with follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Gascoyne,et al. Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. , 2005 .
[8] B. Coiffier. Current strategies for the treatment of diffuse large B cell lymphoma , 2005, Current opinion in hematology.
[9] W. Hiddemann,et al. Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) , 2005 .
[10] A. Hagenbeek,et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] B. Coiffier. Monoclonal antibodies in the treatment of indolent lymphomas. , 2005, Best practice & research. Clinical haematology.
[12] J. Hainsworth,et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[14] P. Solal-Céligny,et al. Follicular lymphoma international prognostic index , 2006, Blood.
[15] G. Salles,et al. Rituximab Added αIFN+CHVP Improves the Outcome of Follicular Lymphoma Patients with a High Tumor Burden: to First Analysis of the GELA-GOELAMS FL-2000 Randomized Trial in 359 Patients. , 2004 .
[16] D. Niederwieser,et al. Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL). , 2004 .
[17] M. Ghielmini,et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.
[18] M. Sydes,et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. Fatovich. Responses to access block in Australia: Royal Perth Hospital , 2003, The Medical journal of Australia.
[20] C. Bloomfield,et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. López-Guillermo,et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] T. Lister,et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma , 2001, British Journal of Cancer.
[23] R. Fisher,et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] B. Cheson,et al. Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] L. Gordon,et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Rossi,et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. Zamora,et al. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Hagenbeek,et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Demidem,et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. , 1997, Cancer biotherapy & radiopharmaceuticals.
[31] P. Solal-Céligny. 3 Management of histologically indolent non-Hodgkin's lymphomas , 1996 .
[32] P. Solal-Céligny. Management of histologically indolent non-Hodgkin's lymphomas. , 1996, Bailliere's clinical haematology.
[33] A. Aisenberg,et al. Coherent view of non-Hodgkin's lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] T. Lister,et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Chinn,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.
[36] B. Coiffier,et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. , 1993, The New England journal of medicine.
[37] S. Horning. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.
[38] B. Nathwani,et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Oken,et al. Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] D. Deakin,et al. Maintenance chlorambucil after CVP in the management of advanced stage, low‐grade histologic type non‐Hodgkin's lymphoma: A randomized prospective study with an assessment of prognostic factors , 1988, Cancer.
[41] M. O’connell,et al. The effect of intensive intermittent maintenance therapy in advanced low‐grade non‐Hodgkin's lymphoma , 1987, Cancer.
[42] T. Lister,et al. Follicular lymphoma: prognostic factors for response and survival. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Don Kelly. Hotel Dieu Hospital , 1910 .
[44] Références , 2022, Revue annuelle du marché des produits forestiers 2019-2020.
[45] THE HAGUE-THE NETHERLANDS , 2022 .